Poolbeg Pharma: POLB 001 Clinical Data Published — What’s Next for This Immunomodulatory Asset?
Following the publication of a peer-reviewed paper in Frontiers in Immunology detailing results from the POLB 001 LPS challenge trial, we catch up with Poolbeg Pharma's CEO Jeremy Skillington and COO Liam Tremble. Liam explains why this publication is a key validation milestone for POLB 001 and how it supports continued clinical development, including the upcoming TOPICAL trial. Jeremy provides an update on trial preparations, outlines interest from potential partners, and addresses a recent option exercise announcement involving former employees. This timely discussion offers investors fresh insights into Poolbeg’s 2024 roadmap.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
